Acute Promyelocytic Leukemia (PML-RARA) · line 1 · ATRA + Arsenic Trioxide (APL low/intermediate-risk) — APL0406 / LO-CoCo schedule
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ATRA-ATO-APL |
| ID | IND-APL-1L-ATRA-ATO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-APL0406-LOCOCO-2013 SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Notes
STANDARD track for low/intermediate-risk APL. time_critical: true reflects CHARTER §15.2 C2 — APL initial management is partially outside the non-device CDS carve-out (ATRA initiation must be at bedside within hours, not via this tool). OpenOnco scope: workup + plan AFTER initial stabilization. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-APL-1L- ALGO-APL-1L
Indication
IND-APL-1L-ATRA-ATO-IDA- IND-APL-1L-ATRA-ATO-IDA